First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: PIK3CA Mutation|Solid Tumor, Adult|HER2-negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Unresectable Solid Tumor|Hormone Receptor Positive Tumor
Interventions: DRUG: RLY-5836|DRUG: Fulvestrant|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: Abemaciclib
Sponsor: Relay Therapeutics, Inc.